News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Asembia 2025 |
Sales Effectiveness|
Latest Executive Roundtables
Advertisement

Jason Evers

Advertisement

Articles by Jason Evers

Reducing the Risk of Noncompliance

ByJason Evers,Maria Gordian
February 8th 2017

The key steps to easing rising complexity and cost factors.

Advertisement

Latest Updated Articles

  • Reducing the Risk of Noncompliance
    Reducing the Risk of Noncompliance

    Published: February 8th 2017 | Updated:



Advertisement
Advertisement

Trending on PharmExec

1

FDA Approves Bayer’s Lynkuet as First Dual Neurokinin Antagonist for Menopausal Hot Flashes

2

TrumpRx and the Dawn of Direct-to-Consumer Commercialization

3

FDA Approves Blenrep for Treatment of Replapsed/Refractory Multiple Myeloma

4

Pharmaceutical Executive Daily: TrumpRx's Implication on DTC Commercialization

5

Lilly Enters Definitive Agreement Acquiring Aderum Biotechnologies

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us